Cited 32 times in
PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.contributor.author | 장향란 | - |
dc.contributor.author | 정민규 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 박지수 | - |
dc.date.accessioned | 2016-02-04T10:52:30Z | - |
dc.date.available | 2016-02-04T10:52:30Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 0030-2414 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139170 | - |
dc.description.abstract | BACKGROUND: To investigate the role of the phosphoinositide 3-kinase (PI3K) pathway activation in human epidermal growth factor receptor 2 (HER2)-targeted therapy. METHODS: We evaluated the predictive roles of PI3K, catalytic alpha (PIK3CA), and phosphatase and tensin homolog (PTEN) in HER2-based therapy (either trastuzumab or lapatinib). PTEN expression and PIK3CA mutation were analyzed using immunohistochemistry and pyrosequencing. RESULTS: Forty-eight patients received trastuzumab (n = 39) or lapatinib (n = 9) combination chemotherapy. PTEN loss was found in 47.9% (n = 23), but no PIK3CA mutations were identified. Twenty-six (54.1%) patients responded to HER2-based therapy, without a significant difference between patients with PTEN loss and those without (52.2 vs. 56.0%). Among the patients with responsive disease, time to best response did not differ by PTEN status, but the duration of response was significantly shorter for patients with PTEN loss (median 4.2 vs. 6.1 months, p = 0.04). In addition, patients with PTEN loss had a significantly shorter progression-free survival time (median 4.9 vs. 7.3 months, p = 0.047). CONCLUSIONS: PTEN deficiency is an important predictive marker for early resistance to HER2 inhibitor treatment in gastric cancer patients. This finding may be useful for the development of drug combinations and identification of patients who need a modified treatment strategy. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Biomarkers | - |
dc.subject.MESH | Class I Phosphatidylinositol 3-Kinases | - |
dc.subject.MESH | Drug Resistance, Neoplasm | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | PTEN Phosphohydrolase/analysis | - |
dc.subject.MESH | PTEN Phosphohydrolase/deficiency* | - |
dc.subject.MESH | Phosphatidylinositol 3-Kinases/antagonists & inhibitors | - |
dc.subject.MESH | Phosphatidylinositol 3-Kinases/genetics | - |
dc.subject.MESH | Receptor, ErbB-2/antagonists & inhibitors* | - |
dc.subject.MESH | Stomach Neoplasms/chemistry | - |
dc.subject.MESH | Stomach Neoplasms/drug therapy* | - |
dc.subject.MESH | Stomach Neoplasms/genetics | - |
dc.subject.MESH | Stomach Neoplasms/mortality | - |
dc.title | PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer | - |
dc.type | Article | - |
dc.contributor.college | Researcher Institutes (부설 연구소) | - |
dc.contributor.department | Oral Cancer Research Institute (구강종양연구소) | - |
dc.contributor.googleauthor | Zhang X | - |
dc.contributor.googleauthor | Park JS | - |
dc.contributor.googleauthor | Park KH | - |
dc.contributor.googleauthor | Kim KH | - |
dc.contributor.googleauthor | Jung M | - |
dc.contributor.googleauthor | Chung HC | - |
dc.contributor.googleauthor | Rha SY | - |
dc.contributor.googleauthor | Kim HS. | - |
dc.identifier.doi | 10.1159/000366426 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A03489 | - |
dc.contributor.localId | A03606 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J02416 | - |
dc.identifier.eissn | 1423-0232 | - |
dc.identifier.pmid | 25300346 | - |
dc.identifier.url | http://www.karger.com/Article/FullText/366426 | - |
dc.subject.keyword | HER2 | - |
dc.subject.keyword | Gastric cancer | - |
dc.subject.keyword | PTEN | - |
dc.subject.keyword | PIK3CA | - |
dc.subject.keyword | Trastuzumab | - |
dc.subject.keyword | Lapatinib | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Zhang, Xiang Lan | - |
dc.contributor.alternativeName | Jung, Min Kyu | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Zhang, Xiang Lan | - |
dc.contributor.affiliatedAuthor | Jung, Min Kyu | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 88 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 76 | - |
dc.citation.endPage | 85 | - |
dc.identifier.bibliographicCitation | ONCOLOGY, Vol.88(2) : 76-85, 2015 | - |
dc.identifier.rimsid | 43808 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.